INBX PDUFA date: INBRX-106
198 business days to decision · 2027-04-14
Inhibrx Biosciences, Inc.'s INBRX-106 for Head and Neck Squamous Cell Carcinoma (HNSCC) — FDA decision expected April 14, 2027.
Key facts
PDUFA date2027-04-14
Business days away198
Drug / candidateINBRX-106
IndicationHead and Neck Squamous Cell Carcinoma (HNSCC)
CompanyInhibrx Biosciences, Inc.
Market-cap tierSmall
Cohort decision-day move (history)±3% median
Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction. See the full 2026 PDUFA calendar →
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio